Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
May 12, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
April 06, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
INCYSUS THERAPEUTICS TO PRESENT AT THE NYC SPRING ONCOLOGY INVESTOR CONFERENCE
March 31, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Incysus Therapeutics Announces Issuance of Foundational U.S. Patent Covering Use of Drug Resistant Immunotherapy (DRI) Technology for the Treatment of Cancer
January 29, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at Biotech Showcase 2020
January 09, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Participate in Evercore ISI HealthCONx Conference
November 26, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
November 21, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the New York Oncology Investor Conference
November 07, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the 2019 Bio Investor Forum
October 22, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit
September 10, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...